ADC Therapeutics SA
ADCT
$3.43
-$0.05-1.44%
NYSE
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -9.57% | 40.37% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -9.57% | 40.37% | |||
| Cost of Revenue | 33.48% | -37.16% | |||
| Gross Profit | -148.38% | 147.15% | |||
| SG&A Expenses | 5.42% | 12.77% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 18.07% | -16.97% | |||
| Operating Income | -57.95% | 47.75% | |||
| Income Before Tax | -383.90% | 83.37% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -414.40% | 84.36% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -414.40% | 84.36% | |||
| EBIT | -57.95% | 47.75% | |||
| EBITDA | -56.85% | 47.75% | |||
| EPS Basic | -508.69% | 85.81% | |||
| Normalized Basic EPS | -698.03% | 89.08% | |||
| EPS Diluted | -508.69% | 85.81% | |||
| Normalized Diluted EPS | -698.03% | 89.08% | |||
| Average Basic Shares Outstanding | -15.39% | 10.15% | |||
| Average Diluted Shares Outstanding | -15.39% | 10.15% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||